Syros Pharmaceuticals, Inc. (SYRS)
NASDAQ: SYRS · Real-Time Price · USD
2.430
+0.165 (7.28%)
Nov 4, 2024, 4:00 PM EST - Market closed
Syros Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Cash & Equivalents | 58.28 | 139.53 | 167.47 | 92.3 | 173.98 | 41.44 | Upgrade
|
| Short-Term Investments | - | - | 34.84 | 38.07 | - | 49.98 | Upgrade
|
| Cash & Short-Term Investments | 58.28 | 139.53 | 202.3 | 130.37 | 173.98 | 91.42 | Upgrade
|
| Cash Growth | -48.07% | -31.03% | 55.18% | -25.07% | 90.32% | -8.29% | Upgrade
|
| Receivables | - | - | 1.69 | 2.98 | 2.33 | 20.16 | Upgrade
|
| Prepaid Expenses | 5.66 | 5.45 | 7.39 | 3.24 | 2.24 | 2.65 | Upgrade
|
| Restricted Cash | - | - | - | - | - | 0.29 | Upgrade
|
| Total Current Assets | 63.93 | 144.98 | 211.39 | 136.59 | 178.56 | 114.51 | Upgrade
|
| Property, Plant & Equipment | 17.58 | 19.48 | 24.66 | 27.29 | 29.64 | 31.89 | Upgrade
|
| Long-Term Investments | - | - | - | 13.04 | - | - | Upgrade
|
| Other Long-Term Assets | 3.49 | 3.71 | 8.43 | 6.03 | 5.05 | 3.58 | Upgrade
|
| Total Assets | 85 | 168.17 | 244.49 | 182.94 | 213.25 | 149.98 | Upgrade
|
| Accounts Payable | 9.65 | 11.54 | 6.41 | 3.69 | 3.6 | 5.85 | Upgrade
|
| Accrued Expenses | 16.16 | 16.15 | 17.97 | 15.62 | 11.08 | 10.65 | Upgrade
|
| Current Portion of Long-Term Debt | - | 6.67 | - | - | - | - | Upgrade
|
| Current Portion of Leases | 2.58 | 2.32 | 2.07 | 2.01 | 1.73 | 1.28 | Upgrade
|
| Current Unearned Revenue | - | - | 4.33 | 10.18 | 12.21 | 5.74 | Upgrade
|
| Total Current Liabilities | 28.39 | 36.68 | 30.78 | 31.51 | 28.62 | 23.52 | Upgrade
|
| Long-Term Debt | 41.08 | 34.56 | 40.65 | 40.26 | 39.55 | - | Upgrade
|
| Long-Term Leases | 16.56 | 18.53 | 20.85 | 22.92 | 24.93 | 24.64 | Upgrade
|
| Long-Term Unearned Revenue | - | - | - | - | 9.88 | 22.64 | Upgrade
|
| Other Long-Term Liabilities | 10.08 | 61.75 | 24.47 | 3.03 | 19.71 | - | Upgrade
|
| Total Liabilities | 96.12 | 151.51 | 116.75 | 97.72 | 122.7 | 70.79 | Upgrade
|
| Common Stock | 0.03 | 0.03 | 0.02 | 0.01 | 0.06 | 0.04 | Upgrade
|
| Additional Paid-In Capital | 745.09 | 739.44 | 685.85 | 548.87 | 467.52 | 372.1 | Upgrade
|
| Retained Earnings | -756.24 | -722.81 | -558.23 | -463.58 | -377.02 | -292.98 | Upgrade
|
| Comprehensive Income & Other | - | - | 0.1 | -0.08 | - | 0.02 | Upgrade
|
| Total Common Equity | -11.12 | 16.66 | 127.74 | 85.22 | 90.55 | 79.18 | Upgrade
|
| Shareholders' Equity | -11.12 | 16.66 | 127.74 | 85.22 | 90.55 | 79.18 | Upgrade
|
| Total Liabilities & Equity | 85 | 168.17 | 244.49 | 182.94 | 213.25 | 149.98 | Upgrade
|
| Total Debt | 60.23 | 62.08 | 63.57 | 65.19 | 66.21 | 25.92 | Upgrade
|
| Net Cash (Debt) | -1.95 | 77.45 | 138.73 | 78.22 | 107.77 | 65.5 | Upgrade
|
| Net Cash Growth | - | -44.17% | 77.37% | -27.42% | 64.54% | -34.27% | Upgrade
|
| Net Cash Per Share | -0.05 | 2.73 | 10.98 | 12.51 | 23.40 | 16.28 | Upgrade
|
| Filing Date Shares Outstanding | 26.83 | 26.45 | 20.3 | 6.21 | 6.16 | 4.34 | Upgrade
|
| Total Common Shares Outstanding | 26.83 | 26.45 | 20.26 | 6.2 | 5.62 | 4.34 | Upgrade
|
| Working Capital | 35.54 | 108.3 | 180.61 | 105.08 | 149.93 | 91 | Upgrade
|
| Book Value Per Share | -0.41 | 0.63 | 6.30 | 13.74 | 16.11 | 18.26 | Upgrade
|
| Tangible Book Value | -11.12 | 16.66 | 127.74 | 85.22 | 90.55 | 79.18 | Upgrade
|
| Tangible Book Value Per Share | -0.41 | 0.63 | 6.30 | 13.74 | 16.11 | 18.26 | Upgrade
|
| Machinery | - | 3.28 | 12.25 | 11.04 | 9.77 | 7.88 | Upgrade
|
| Construction In Progress | - | - | - | - | 0.01 | 0.16 | Upgrade
|
| Leasehold Improvements | - | 11.66 | 11.66 | 11.66 | 11.66 | 11.61 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.